21. Antifibrotic Drugs

  1. Roberto de Franchis MD, AGAF Professor of Gastroenterology Head
  1. Massimo Pinzani MD, PhD

Published Online: 17 NOV 2010

DOI: 10.1002/9781444393989.ch21

Portal Hypertension V: Proceedings of the Fifth Baveno International Consensus Workshop, Fifth Edition

Portal Hypertension V: Proceedings of the Fifth Baveno International Consensus Workshop, Fifth Edition

How to Cite

Pinzani, M. (2011) Antifibrotic Drugs, in Portal Hypertension V: Proceedings of the Fifth Baveno International Consensus Workshop, Fifth Edition (ed R. de Franchis), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444393989.ch21

Editor Information

  1. Department of Medical Sciences, University of Milan, and Gastroenterology 3 Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico Mangiagalli and Regina Elena Foundation, Milan, Italy

Author Information

  1. Department of Internal Medicine, Centre for Research, High Education and Transfer “DENOThe”, University of Florence, Italy

Publication History

  1. Published Online: 17 NOV 2010
  2. Published Print: 14 JAN 2011

ISBN Information

Print ISBN: 9781444334494

Online ISBN: 9781444393989

SEARCH

Keywords:

  • antifibrotic drugs;
  • hepatic fibrogenesis, typical of chronic liver disease (CLD) - reflecting chronic-wound healing reaction, to chronic liver tissue damage;
  • hepatic stellate cells (HSC) cultures - isolated from rodent or human liver;
  • antifibrogenic agents and their features;
  • potential antifibrogenic action of antiviral drugs;
  • antiviral treatment (AVT), acting against fibrosis - reduction of liver damage, consequent to viral load reduction;
  • angiotensin II receptor blockers;
  • antioxidants and “herbal” drugs;
  • probiotics, and other strategies - modulating gut flora;
  • pathogenic role of conserved pathogen-associated molecular patterns (PAMPs) - and putative contribution to myofibroblast activation

Summary

This chapter contains sections titled:

  • Introduction

  • General features of antifibrogenic agents

  • The potential antifibrogenic action of antiviral drugs

  • Angiotensin II receptor blockers

  • Antioxidants and “herbal” drugs

  • Probiotics and other strategies to modulate the gut flora: is it worth a try?

  • Antiangiogenic is also antifibrogenic

  • Compensated cirrhosis: the ideal ground for experimenting antifibrotic drugs

  • References